The impact of combination therapy with Femoklim and Nervo-Vit on the psychological state of women with estrogen deficiency and metabolically healthy obesity

DOI: https://doi.org/10.29296/25877305-2022-06-09
Issue: 
6
Year: 
2022

M. Khabibulina, Candidate of Medical Sciences; M. Shamilov
Ural State Medical University, Yekaterinburg

Therapy with the natural non-hormonal drug Femoklim and the combined sedative drug Nervo-Vit was evaluated for efficiency in premenopausal patients (n=45) with metabolically healthy abdominal obesity (MHAO), hypoetrogenemia, and psychological changes. The natural non-hormonal remedy Femoklim and the combined natural sedative drug Nervo-Vit have been established to effectively affect the psychological state of patients during menopausal transition with MHAO and estrogen deficiency. The drugs have a complex versatile effect on the female body and make it possible to safely normalize the level of estrogen and to level off the clinical manifestations of estrogen deficiency. All components of the drugs that are physiologically close to the woman’s body and do not disturb its natural processes. Femoklim and Nervo-Vit show high efficacy and low toxicity, a wide spectrum of action, and a complex harmonizing effect on the body
Keywords: 
therapy
psychological state
metabolically healthy obesity
estrogen deficiency
premenopause
Femoklim
Nervo-Vit

References: 
  1. Shevchenko O.P., Praskurnichii E.A., Shevchenko A.O. Metabolicheskii sindrom. M.: Reafarm; 2004 (in Russ.).
  2. Barbato J.E., Zuckerbraun B.S., Overbaus M. et al. Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and metabolic syndrome. J Physiol Heart Circ Physiol. 2005; 289 (1): 228–36. DOI: 10.1152/ajpheart.00982.2004
  3. De Fronzo R.A., Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic disease. Diabetes Care. 1991; 14: 173–94. DOI: 10.2337/diacare.14.3.173
  4. Dupuy A.M., Carriere L., Scali J. et al. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipidlowering agents. Climacteric. 2008; 11: 74–83. DOI: 10.1080/13697130701877108
  5. Rabmouni K., Correia M.L.G., Haynes W.G. et al. Obesity-associated Hypertension. New insights into mechanisms. Hypertension. 2005; 45: 9–14. DOI: 10.1161/01.HYP.0000151325.83008.b4
  6. Khabibulina M.M., Dmitriev A.N., Fedorova N.N. Silent myocardial ischemia in women with arterial hypertension with hypestrogenism in the late fertile period with«metabolically healthy» visceral obesity. Interactive Science. 2017; 12: 81–3 (in Russ.). DOI: 10.21661/r-117894
  7. Khabibulina M.M., Dmitriev A.N., Fedorova N.N. Kachestvo zhizni molodykh zhenshchin s arterial’noi gipertenziei s gipoestrogenemiei s «metabolicheski zdorovym» vistseral’nym ozhireniem. Evraziiskii Soyuz Uchenykh. 2017; 1 (34): 25–9 (in Russ.).
  8. Khabibulina M.M., Dmitriev A.N., Fedorova N.N. Lechenie ataraksom trevozhnykh rasstroistv u zhenshchin s arterial'noi gipertenziei s gipoestrogenemiei v pozdnem fertil'nom periode s «metabolicheski zdorovym» ozhireniem. Mat-ly obrazovatel'nogo foruma «Rossiiskie dni serdtsa». M., 2017; s. 116 (in Russ.).
  9. Anan'ev V.A. Osobennosti diskretnogo tipa lichnosti v etiopatogeneze psikhosomaticheskikh rasstroistv. Vestnik psikhoterapii. 2003; 10 (15): 45–55 (in Russ.).
  10. Kulakov S.A. Osnovy psikhosomatiki. SPb: Rech', 2003; 288 s (in Russ.).
  11. Eidemiller E.G., Yustitskis V. Psikhologiya i psikhoterapiya sem'i. 2-e izd., rasshiren., dop. SPb, 2005; 656 s. (in Russ.).
  12. Rotov A.V., Gavrilov M.A., Bobrovskii A.V. i dr. Agressiya kak forma adaptivnoi psikhologicheskoi zashchity u zhenshchin s izbytochnoi massoi tela. Sibirskii vestnik psikhiatrii i narkologii. 1999; 1: 81–3 (in Russ.).
  13. Alam I., Ng T.P., Larbi A. Does inflammation determine whether obesity is metabolically healthy or unhealthy? The aging perspective. Mediators Inflamm. 2012; 2012: 456456. DOI: 10.1155/2012/456456
  14. Biobank Standardisation and Harmonisation for Research Excellence in the European Union From 2010-12-01 to 2015-11-30, project 261433.
  15. Vliet-Ostaptchouk J.V., Nuotio M.L., Slagter S.N. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014; 14: 9. DOI: 10.1186/1472-6823-14-9
  16. Bobrovskii A.V., Rotov A.V., Gudkov S.V. et al. Vzaimosvyaz' psikhologicheskikh osobennostei lichnosti i massy tela u bol'nykh ekzogenno-konstitutsional'nym ozhireniem. Sibirskii psikhologicheskii zhurnal. 1998; 8–9: 84–5 (in Russ.).
  17. Voznesenskaya T.G., Dorozhevets A.N. Rol' osobennostei lichnosti v patogeneze tserebral'nogo ozhireniya. Sovetskaya meditsina. 1987; 3: 28–32 (in Russ.).
  18. Ryden A., Sullivan M., Torgerson J.S. et al. Severe obesity and personality: a comparative controlled study of personality traits. Int J Obes Relat Metab Disord. 2003; 27 (12): 1534–40. DOI: 10.1038/sj.ijo.0802460
  19. Khabibulina M.M. Effect of hypoestrogenemia on quality of life of premenopausal women with arterial hypertension. Kardiologiya. 2013; 53 (11): 45–8 (in Russ.).
  20. Khabibulina M., Shamilov M. Quality of life in young women with hypertension and an altered hormonal background. Vrach. 2021; 32 (1): 46–9 (in Russ.). DOI: 10.29296/25877305-2021-01-09 (in Russ.).
  21. Blumel J.E., Castello C. et al. Quality of life after the menopause – a population study. Maturitas. 2009; 34 (1): 17–23. DOI: 10.1016/s0378-5122(99)00081-x
  22. Stein K.D., Jacobsen P.B. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom. 2009; 19: 436–45.
  23. Dedov D.V., Mazaev V. P., Ryazanova S. V. et al. Study of quality of life in interventional and conservative treatment of patients with stable angina pectoris at long-term follow-up. Cardiovascular therapy and prevention. 2014; 13 (5). 31–5 (in Russ.). DOI: 10.15829/1728-8800-2014-5-31-35
  24. Khabibulina M.M. Kardiovaskulyarnyi risk pri estrogenodefitsite v doklimaktericheskikh periodakh.Yekaterinburg, 2014 (in Russ.).
  25. Khabibulina M.M., Smolentseva A.A. Terapiya trevozhnykh rasstroistv u zhenshchin s arterial'noi gipertenziei v period premenopauzy na ambulatornom etape. V sb.: V s"ezd kardiologov Ural'skogo federal'nogo okruga. Mat-ly s"ezda. 2011; s. 282–4 (in Russ.).
  26. Skornyakova M.N., Syrochkina M.A. Gipomenstrual'nyi sindrom. Rukovodstvo dlya vrachei. Ekaterinburg, 2008; 236 s. (in Russ.).
  27. Smetnik V.P., Il'ina L.M. Korrektsiya klimaktericheskogo sindroma (individualizatsiya terapii). V kn. «Meditsina klimakteriya». Litera, 2006; s. 217–74 (in Russ.).
  28. Ilovaiskaya I.A., Voitashevskii K.V. Menopauzal'naya gormonal'naya terapiya: vozmozhnosti i riski. Status Praesens. Ginekologiya. Akusherstvo. Besplodnyi brak. 2015; 5 (28): 80–6 (in Russ.).
  29. Menopauzal'naya gormonal'naya terapiya i sokhranenie zdorov'ya zhenshchin zrelogo vozrasta: Klinicheskie rekomendatsii (protokol lecheniya). M.: FGBU NTsGAiP, 2015 (in Russ.).
  30. Sturdee D.W., Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health Group. Climacteric. 2011; 14: 302–20. DOI: 10.3109/13697137.2011.570590
  31. Khabibulina M.M., Dmitriev A.N. Sposob optimizatsii lecheniya zhenshchin kardiotropnoi terapiei i zamestitel'noi gormonal'noi terapiei pri estrogenodefitsite s arterial'noi gipertenziei v pozdnem reproduktivnom periode. Patent na izobretenie RU 2648470 C2, 26.03.2018 Zayavka №2016107890 ot 03.03.2016 (in Russ.).
  32. Khabibulina M. Therapy in women with hypertension and estrogen deficiency in the late fertile period. Vrach. 2016; 4: 45–9 (in Russ.).
  33. Speilberger C., Gorusch R., Lushene R. Test Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, 1970; 280 р.
  34. Khanin Yu.L. Kratkoe rukovodstvo k primeneniyu shkaly reaktivnoi i lichnostnoi trevozhnosti Ch.D. Speilberger. L., 1976; 40 s. (in Russ.).
  35. Van Strien, T., Herman C.P., Verheijden M.W. Eating style, overeating, and overweight in a representative Dutch sample: Does external eating play a role? Appetite. 2008; 52 (2): 380–7. DOI: 10.1016/j.appet.2008.11.010
  36. Ovsyannikova T.V., Makarov I.O., Kulikov I.A. Clinical efficacy of non-hormonal methods of therapy in perimenopausal women. Obstetrics, Gynecology and Reproduction. 2013; 7 (3): 26–9 (in Russ.).
  37. Petrova E., Kalistratov V., Polyboyarinov P. et al. The menopause drug Femo-Klim is the best nonhormonal solution of hormonal problems. Vrach. 2019; 30 (1): 46–9 (in Russ.). DOI: 10.29296/25877305-2019-01-08
  38. Radzinskii V.E., Dobretsova T.A. Menopauza kak mekhanizm zhenskogo stareniya. Fitoestrogeny – razvedka boem. StatusPraesens. Ginekologiya. Akusherstvo. Besplodnyi brak. 2015; 2 (25): 51–8 (in Russ.).
  39. Tatarova N.A., Linde V.A., Zhidkova E.V. et al. Negormonal'naya korrektsiya klimaktericheskikh rasstroistv v peri- i postmenopauze. Effektivnaya farmakoterapiya v akusherstve i ginekologii. 2009; 17: 12–5 (in Russ.).
  40. Khamoshina M.B., Rogovskaya S.I., Naumchik G.A. Aktual'nye vozmozhnosti farmakologii v profilaktike vozrastnykh narushenii. StatusPraesens. Ginekologiya. Akusherstvo. Besplodnyi brak. 2014; 1 (18): 75–81